THERAPY DOSSIER · th-bd5367045eb6

Dehydrocrenatidine (DHCT), a beta-carboline alkaloid

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31003411 ↗2019Reported benefit

Dehydrocrenatidine Inhibits Voltage-Gated Sodium Channels and Ameliorates Mechanic Allodia in a Rat Model of Neuropathic Pain.

RatOtherSprague-Dawleymalen = 5 groups of 9 rats each (n = 9 per group); electrophysiolog…intrathecal injection150 or 250 microgram/kg14 days after chronic constriction injury, once mechanical allodynia was establ…

Model: Chronic constriction injury (partial ligation) of the sciatic nerve, neuropathic pain

Chronic constriction injury reduced paw withdrawal threshold to 1.90 +/- 0.31 g versus 15.10 +/- 1.50 g in sham. Intrathecal dehydrocrenatidine dose-dependently reversed mechanical allodynia, with the 250 microgram/kg dose comparable to morphine 50 microgram/kg. DHCT suppressed TTX-S and TTX-R sodi…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…